These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23085103)

  • 1. In search of the neuroprotective mechanism of thiazolidinediones in Parkinson's disease.
    Ridder DA; Schwaninger M
    Exp Neurol; 2012 Dec; 238(2):133-7. PubMed ID: 23085103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease.
    Martin HL; Mounsey RB; Mustafa S; Sathe K; Teismann P
    Exp Neurol; 2012 Jun; 235(2):528-38. PubMed ID: 22417924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease.
    Carta AR; Simuni T
    Expert Opin Investig Drugs; 2015 Feb; 24(2):219-27. PubMed ID: 25227476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study.
    Brauer R; Bhaskaran K; Chaturvedi N; Dexter DT; Smeeth L; Douglas I
    PLoS Med; 2015 Jul; 12(7):e1001854. PubMed ID: 26196151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.
    Tureyen K; Kapadia R; Bowen KK; Satriotomo I; Liang J; Feinstein DL; Vemuganti R
    J Neurochem; 2007 Apr; 101(1):41-56. PubMed ID: 17394460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.
    Laloux C; Petrault M; Lecointe C; Devos D; Bordet R
    Pharmacol Res; 2012 May; 65(5):514-22. PubMed ID: 22391246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
    Carta AR; Frau L; Pisanu A; Wardas J; Spiga S; Carboni E
    Neuroscience; 2011 Oct; 194():250-61. PubMed ID: 21839812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms.
    Yi JH; Park SW; Brooks N; Lang BT; Vemuganti R
    Brain Res; 2008 Dec; 1244():164-72. PubMed ID: 18948087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones.
    Tagami T; Yamamoto H; Moriyama K; Sawai K; Usui T; Shimatsu A; Naruse M
    Endocrinology; 2009 Feb; 150(2):862-70. PubMed ID: 19147680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice.
    Lecca D; Nevin DK; Mulas G; Casu MA; Diana A; Rossi D; Sacchetti G; Fayne D; Carta AR
    Neuroscience; 2015 Aug; 302():23-35. PubMed ID: 25907448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent trends in PPARgamma agonist development of thiazolidinediones and non-thiazolidinediones].
    Tanaka T
    Nihon Rinsho; 2010 Feb; 68(2):249-55. PubMed ID: 20158092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage.
    Garcia-Vallvé S; Guasch L; Tomas-Hernández S; del Bas JM; Ollendorff V; Arola L; Pujadas G; Mulero M
    J Med Chem; 2015 Jul; 58(14):5381-94. PubMed ID: 25734377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: implication of ERK1/2 and PPARgamma receptors.
    Rosa AO; Egea J; Martínez A; García AG; López MG
    Exp Neurol; 2008 Jul; 212(1):93-9. PubMed ID: 18471812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinediones inhibit albumin uptake by proximal tubular cells through a mechanism independent of peroxisome proliferator activated receptor gamma.
    Chana RS; Brunskill NJ
    Am J Nephrol; 2006; 26(1):67-74. PubMed ID: 16508249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased risk of Parkinson's disease in diabetic patients with thiazolidinediones therapy: An exploratory meta-analysis.
    Zhu Y; Pu J; Chen Y; Zhang B
    PLoS One; 2019; 14(10):e0224236. PubMed ID: 31639149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A peroxisome proliferator-activated receptor gamma agonist attenuates neurological deficits following spinal cord ischemia in rats.
    Kim H; Hwang J; Park S; Nahm SF; Min S; Lim C; Park K; Han S
    J Vasc Surg; 2014 Apr; 59(4):1084-9. PubMed ID: 23830318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular determinants of PPARγ partial agonism and related in silico/in vivo studies of natural saponins as potential type 2 diabetes modulators.
    Al Sharif M; Alov P; Diukendjieva A; Vitcheva V; Simeonova R; Krasteva I; Shkondrov A; Tsakovska I; Pajeva I
    Food Chem Toxicol; 2018 Feb; 112():47-59. PubMed ID: 29247773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARβ/δ and γ in a rat model of Parkinson's disease: possible involvement in PD symptoms.
    Falcone R; Florio TM; Di Giacomo E; Benedetti E; Cristiano L; Antonosante A; Fidoamore A; Massimi M; Alecci M; Ippoliti R; Giordano A; Cimini A
    J Cell Biochem; 2015 May; 116(5):844-55. PubMed ID: 25530507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents.
    Kaundal RK; Sharma SS
    Drug News Perspect; 2010 May; 23(4):241-56. PubMed ID: 20520853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression.
    Sadeghian M; Marinova-Mutafchieva L; Broom L; Davis JB; Virley D; Medhurst AD; Dexter DT
    J Neuroimmunol; 2012 May; 246(1-2):69-77. PubMed ID: 22498097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.